Robert Mitchell edits the MedTech and Healthcare Services desk at Trend & Ticker. He covers medical device makers, diagnostics companies, hospital operators and healthcare services companies. His coverage is built on company filings, product clearances and official health data, and he checks every figure against its source before a story runs.
Recent Actualizat
-
Natera (NTRA) draws a Buy and a $475 target as Roth/MKM bets on cancer residual disease testsRoth/MKM started coverage of Natera, Inc. (NTRA) at Buy with a $475 target, pointing to wider use of its minimal residual disease blood tests, firmer pricing and a 2027 early detection study readout. Roth/MKM started coverage of Natera, Inc. (NTRA) on Friday, October 23, 2026, with a Buy rating and a $475 price target, Investing.com reported. The firm built its case on the company's cancer...0 Commentarii 0 Distribuiri 6 Views 0 previzualizareVă rugăm să vă autentificați pentru a vă dori, partaja și comenta!
-
0 Commentarii 0 Distribuiri 4 Views 0 previzualizare
Mai multe povesti